Open AccessOmalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
Author(s) -
J. Just,
C. Thonnelier,
M. Bourgoin-Heck,
Lenka Malá,
Mathiéu Molimard,
Marc Humbert
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s310888
Subject(s) - omalizumab , medicine , exacerbation , asthma , immunoglobulin e , post hoc analysis , allergy , food allergy , immunology , antibody
Immunoglobulin (Ig) E-mediated pathophysiological mechanisms are common in allergic diseases including severe allergic asthma (SAA). The anti-IgE monoclonal antibody omalizumab may be particularly beneficial for patients with SAA and multiple allergic comorbidities (AC) including perennial/seasonal rhinitis, conjunctivitis, atopic dermatitis (AD), and food allergy.